Rapid, High-Throughput Format Scouting for Multi-Specific Antibodies with mAbForge™ Multi

Multi-specific antibody format scouting is a bottleneck.

Testing clones across multiple structural architectures requires significant investment before there’s data to justify the choices, and the cost of getting format wrong doesn’t surface until it’s expensive to fix.

Alloy’s mAbForge™ Multi changes the economics of that decision. It enables mammalian expression and combinatorial screening of hundreds of msAb clones, across nearly any format, in a matter of weeks.

Inside the poster:

  • How mAbForge Multi integrates with Alloy’s binding arm discovery platforms: ATX-Gx™ in vivo discovery, Bring Your Own Binder (BYOB), and the Alloy Design Studio to de-risk inputs before format exploration begins

 

  • The mAbForge Multi workflow: from modular building blocks (IgG, Fab, scFv, VHH, DARPin) to a ranked lead set in as few as 4 weeks

 

  • A biparatopic case study: 30 CLC antibody clones screened across four format architectures, filtering over 300 constructs to 3 leads with enhanced internalization, increased avidity, and clean biophysical profiles in 4 weeks
Complete this form to download the poster and learn more about mAbForge™ Multi

Discover how mAbForge™ Multi enables:

  • Combinatorial format screening at scale with hundreds of msAb constructs expressed and tested in CHO cells within a single campaign
  • Format-agnostic architecture with 1+1 and 2+2 symmetrical and asymmetrical designs available across all major building block classes
  • Simultaneous multiparameter assessment for purity, aggregation, fragmentation, affinity, and cell binding, all evaluated in parallel.
    Down-selection in 3–4 weeks from a broad construct library to a focused lead panel ready for deep functional characterization
  • Discovery starting from high-quality inputs — Fabs, scFvs, or VHHs from ATX-Gx™ in vivo discovery, ATX-CLC common light chain platform, or bring-your-own-binders

Alloy Therapeutics supports more than 200 partners globally across 100+ active drug programs, enabling teams to move further, faster against the most complex biologics challenges.